Back to top
more

Eagle Pharmaceuticals (EGRX)

(Real Time Quote from BATS)

$4.97 USD

4.97
54,171

+0.17 (3.54%)

Updated Apr 23, 2024 02:46 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (149 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Down -33.75% in 4 Weeks, Here's Why Eagle Pharmaceuticals (EGRX) Looks Ripe for a Turnaround

by Zacks Equity Research

Eagle Pharmaceuticals (EGRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down -26.73% in 4 Weeks, Here's Why Eagle Pharmaceuticals (EGRX) Looks Ripe for a Turnaround

by Zacks Equity Research

The heavy selling pressure might have exhausted for Eagle Pharmaceuticals (EGRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Canopy Growth Corporation (CGC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Canopy Growth Corporation (CGC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Implied Volatility Surging for Eagle Pharmaceuticals (EGRX) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Eagle Pharmaceuticals (EGRX) stock based on the movements in the options market lately.

Indrajit Bandyopadhyay headshot

4 Undervalued Medical Stocks to Buy Amid High Market Volatility

by Indrajit Bandyopadhyay

Amid volatility, undervalued companies with solid prospects cushion investors from market jitters, while their robust fundamentals ensure higher returns. ACHC, PGNY, EGRX and NRBO are four such stocks.

Is Eagle Pharmaceuticals (EGRX) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Eagle Pharmaceuticals (EGRX) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 12.38% and 8.92%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Haemonetics (HAE) Surges 5.2%: Is This an Indication of Further Gains?

by Zacks Equity Research

Haemonetics (HAE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Eagle Pharmaceuticals (EGRX) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 5.88% and 3.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Maravai LifeSciences Holdings, Inc. (MRVI) Lags Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Maravai LifeSciences Holdings, Inc. (MRVI) delivered earnings and revenue surprises of -25% and 0.86%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Chimerix (CMRX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Chimerix (CMRX) delivered earnings and revenue surprises of 0% and 19.14%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Eagle Pharmaceuticals (EGRX) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 41.03% and 2.90%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Should Value Investors Buy Eagle Pharmaceuticals (EGRX) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Are Investors Undervaluing Eagle Pharmaceuticals (EGRX) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Eagle Pharmaceuticals (EGRX) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 33.33% and 11.01%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Is Eagle Pharmaceuticals (EGRX) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

NuVasive (NUVA) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

NuVasive (NUVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New Strong Sell Stocks for September 26th

by Zacks Equity Research

EGRX, ACCO and ATUS have been added to the Zacks Rank #5 (Strong Sell) List on September 26, 2022.

New Strong Sell Stocks for September 9th

by Zacks Equity Research

EGRX, TWTR and PLAY have been added to the Zacks Rank #5 (Strong Sell) List on September 9, 2022.

New Strong Sell Stocks for September 1st

by Zacks Equity Research

CCCS, BJRI and EGRX have been added to the Zacks Rank #5 (Strong Sell) List on September 1, 2022.

Eli Lilly (LLY) Stock Up More Than 15% YTD: What Lies Ahead?

by Zacks Equity Research

Lilly (LLY) expects to launch five new medicines by 2023-end including Mounjaro for type II diabetes (already launched) and donanemab for early Alzheimer's disease.

Eli Lilly's (LLY) Potential New Products Key to Growth

by Zacks Equity Research

Lilly (LLY) expects to launch five new medicines by 2023 end including Mounjaro for type II diabetes (already launched) and donanemab for early Alzheimer's disease.

Eagle Pharmaceuticals (EGRX) Q2 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of -50.16% and 31.44%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Maravai LifeSciences Holdings, Inc. (MRVI) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Maravai LifeSciences Holdings, Inc. (MRVI) delivered earnings and revenue surprises of 20% and 3.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

TEVA Beats on Q2 Earnings, to Settle Opioid Lawsuit for $4.3B

by Zacks Equity Research

TEVA reports mixed Q2 results. It lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact. The company agrees to settle opioid lawsuits for as much as $4.25 billion.